|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CIB1 |
Gene summary for CIB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CIB1 | Gene ID | 10519 |
| Gene name | calcium and integrin binding 1 | |
| Gene Alias | CIB | |
| Cytomap | 15q26.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q99828 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10519 | CIB1 | GSM4909282 | Human | Breast | IDC | 2.43e-15 | 4.63e-01 | -0.0288 |
| 10519 | CIB1 | GSM4909286 | Human | Breast | IDC | 4.79e-06 | -3.36e-01 | 0.1081 |
| 10519 | CIB1 | GSM4909290 | Human | Breast | IDC | 6.75e-03 | 3.10e-01 | 0.2096 |
| 10519 | CIB1 | GSM4909291 | Human | Breast | IDC | 1.51e-09 | 5.04e-01 | 0.1753 |
| 10519 | CIB1 | GSM4909293 | Human | Breast | IDC | 3.12e-03 | 1.72e-01 | 0.1581 |
| 10519 | CIB1 | GSM4909294 | Human | Breast | IDC | 3.34e-03 | 2.40e-01 | 0.2022 |
| 10519 | CIB1 | GSM4909296 | Human | Breast | IDC | 4.88e-08 | 2.47e-01 | 0.1524 |
| 10519 | CIB1 | GSM4909297 | Human | Breast | IDC | 4.39e-09 | -2.56e-01 | 0.1517 |
| 10519 | CIB1 | GSM4909304 | Human | Breast | IDC | 5.91e-67 | 8.85e-01 | 0.1636 |
| 10519 | CIB1 | GSM4909306 | Human | Breast | IDC | 1.25e-07 | 3.58e-01 | 0.1564 |
| 10519 | CIB1 | GSM4909307 | Human | Breast | IDC | 1.96e-05 | 3.44e-01 | 0.1569 |
| 10519 | CIB1 | GSM4909308 | Human | Breast | IDC | 1.94e-11 | 3.65e-01 | 0.158 |
| 10519 | CIB1 | GSM4909311 | Human | Breast | IDC | 2.56e-24 | -1.47e-01 | 0.1534 |
| 10519 | CIB1 | GSM4909312 | Human | Breast | IDC | 1.08e-04 | 1.25e-04 | 0.1552 |
| 10519 | CIB1 | GSM4909315 | Human | Breast | IDC | 2.32e-10 | 3.85e-01 | 0.21 |
| 10519 | CIB1 | GSM4909319 | Human | Breast | IDC | 5.11e-30 | -3.06e-01 | 0.1563 |
| 10519 | CIB1 | GSM4909321 | Human | Breast | IDC | 2.20e-13 | 1.74e-01 | 0.1559 |
| 10519 | CIB1 | ctrl6 | Human | Breast | Precancer | 7.31e-12 | 6.43e-01 | -0.0061 |
| 10519 | CIB1 | brca2 | Human | Breast | Precancer | 1.05e-24 | 5.10e-01 | -0.024 |
| 10519 | CIB1 | brca3 | Human | Breast | Precancer | 4.76e-11 | 3.63e-01 | -0.0263 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190187911 | Thyroid | ATC | regulation of protein depolymerization | 43/6293 | 87/18723 | 1.62e-03 | 8.14e-03 | 43 |
| GO:003030719 | Thyroid | ATC | positive regulation of cell growth | 74/6293 | 166/18723 | 2.06e-03 | 9.73e-03 | 74 |
| GO:004324412 | Thyroid | ATC | regulation of protein-containing complex disassembly | 56/6293 | 121/18723 | 2.51e-03 | 1.16e-02 | 56 |
| GO:1903706112 | Thyroid | ATC | regulation of hemopoiesis | 148/6293 | 367/18723 | 3.87e-03 | 1.68e-02 | 148 |
| GO:00508483 | Thyroid | ATC | regulation of calcium-mediated signaling | 36/6293 | 73/18723 | 3.91e-03 | 1.70e-02 | 36 |
| GO:0045637113 | Thyroid | ATC | regulation of myeloid cell differentiation | 89/6293 | 210/18723 | 4.75e-03 | 1.96e-02 | 89 |
| GO:190188011 | Thyroid | ATC | negative regulation of protein depolymerization | 35/6293 | 72/18723 | 5.89e-03 | 2.37e-02 | 35 |
| GO:004592720 | Thyroid | ATC | positive regulation of growth | 106/6293 | 259/18723 | 7.90e-03 | 3.06e-02 | 106 |
| GO:00311111 | Thyroid | ATC | negative regulation of microtubule polymerization or depolymerization | 21/6293 | 40/18723 | 1.05e-02 | 3.81e-02 | 21 |
| GO:004349116 | Thyroid | ATC | protein kinase B signaling | 87/6293 | 211/18723 | 1.20e-02 | 4.27e-02 | 87 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CIB1 | insertion | Frame_Shift_Ins | novel | c.258_259insGAGCGTGGAG | p.Ser87GlufsTer44 | p.S87Efs*44 | Q99828 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| CIB1 | SNV | Missense_Mutation | c.43N>A | p.Glu15Lys | p.E15K | Q99828 | protein_coding | deleterious(0.03) | possibly_damaging(0.551) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| CIB1 | SNV | Missense_Mutation | rs771152399 | c.686N>C | p.Ile229Thr | p.I229T | Q99828 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| CIB1 | SNV | Missense_Mutation | novel | c.665N>G | p.Asp222Gly | p.D222G | Q99828 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CIB1 | SNV | Missense_Mutation | novel | c.82N>A | p.Leu28Ile | p.L28I | Q99828 | protein_coding | tolerated(0.11) | benign(0.065) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CIB1 | SNV | Missense_Mutation | c.581N>G | p.Asp194Gly | p.D194G | Q99828 | protein_coding | tolerated(0.09) | benign(0.071) | TCGA-B5-A11G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CIB1 | SNV | Missense_Mutation | rs145803459 | c.656N>A | p.Arg219His | p.R219H | Q99828 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-BG-A220-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CIB1 | SNV | Missense_Mutation | novel | c.248G>T | p.Arg83Leu | p.R83L | Q99828 | protein_coding | tolerated(0.14) | benign(0.168) | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| CIB1 | SNV | Missense_Mutation | c.686T>G | p.Ile229Ser | p.I229S | Q99828 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-G3-A3CK-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CIB1 | SNV | Missense_Mutation | rs765061684 | c.538N>A | p.Glu180Lys | p.E180K | Q99828 | protein_coding | tolerated(0.1) | benign(0.216) | TCGA-39-5031-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |